

Xermelo (telotristat ethyl) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			☐ URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
PATIENT INSURANCE ID NU	JMBER:			
IF YOU ARE NOT THE PATIENT OR THE PRESC	IGHT (IN/CM): WEIGI CRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLO	OSURE AUTHORIZATION FORM WITH THIS REQ	UEST WHICH CAN BE FOUND AT THE	
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:				
PRESCRIBER INFORMATION	N .			
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:		
		1		
MEDICATION OR MEDICAL	DISPENSING INFORMATION			
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
■ NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY	/ INITIATED:	
DURATION OF THERAPY (SP	PECIFIC DATES):			

Continued on next page.





Xermelo (telotristat ethyl) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
□ Carcinoid syndrome □ Other diagnosis:ICD	-10	icb-10.
PRIOR AUTHORIZATION. Clinical Information: Does the patient have a diagnosis of of tumor?* Yes No *Please provide documentation. Will Xermelo be used in combination LAR], etc.)? Yes No Does the patient have an average base	earcinoid syndrome related to well-different with a somatostatin analog (such as octobeline of four or more bowel movement de [Sandostatin, Sandostatin LAR], etc.	erentiated neuroendocrine creotide [Sandostatin, Sandostatin s (BMs) per day while on a
Reauthorization: If this is a reauthorization request, an Has the patient experienced a reducti starting Xermelo (telotristat)? Will the patient continue to use Xerm [Sandostatin, Sandostatin LAR], etc.)?	swer the following questions: on in bowel movement frequency by at No elo in combination with a somatostatin	: least one-third from baseline since
physician feels is important to this rev		
the Health Plan, insurer, Medical Grou information necessary to verify the acc	n provided is true and accurate to the be p or its designees may perform a routine curacy of the information reported on th	e audit and request the medical is form.
Prescriber Signature or Electronic I.D.	verification:	Date:

© 2017 – 2023 by Magellan Rx Management, LLC. All Rights Reserved.

Revision Date: 08/22/2018

CAT0285







Xermelo (telotristat ethyl) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811



Revision Date: 08/22/2018

CAT0285



